BioScrip (BIOS) Upgraded to “Buy” by BidaskClub

BidaskClub upgraded shares of BioScrip (NASDAQ:BIOS) from a hold rating to a buy rating in a research note released on Saturday.

Other equities research analysts have also recently issued reports about the company. Zacks Investment Research upgraded BioScrip from a sell rating to a hold rating in a research note on Wednesday, January 10th. ValuEngine upgraded BioScrip from a strong sell rating to a sell rating in a research note on Thursday, November 9th. Finally, SunTrust Banks reiterated a buy rating and issued a $3.00 price target on shares of BioScrip in a research note on Friday, November 3rd. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $3.63.

Shares of BioScrip (NASDAQ:BIOS) opened at $2.97 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.60 and a debt-to-equity ratio of -6.11. BioScrip has a 12 month low of $1.35 and a 12 month high of $3.39.

A number of institutional investors and hedge funds have recently made changes to their positions in BIOS. Schwab Charles Investment Management Inc. raised its position in BioScrip by 0.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 490,698 shares of the company’s stock valued at $1,333,000 after purchasing an additional 2,622 shares in the last quarter. Bank of New York Mellon Corp raised its position in BioScrip by 6.0% during the second quarter. Bank of New York Mellon Corp now owns 504,459 shares of the company’s stock valued at $1,369,000 after purchasing an additional 28,615 shares in the last quarter. Wells Fargo & Company MN raised its position in BioScrip by 1.0% during the second quarter. Wells Fargo & Company MN now owns 114,810 shares of the company’s stock valued at $312,000 after purchasing an additional 1,100 shares in the last quarter. Alliancebernstein L.P. raised its position in BioScrip by 50.8% during the second quarter. Alliancebernstein L.P. now owns 141,900 shares of the company’s stock valued at $385,000 after purchasing an additional 47,800 shares in the last quarter. Finally, Teachers Advisors LLC raised its position in BioScrip by 10.2% during the second quarter. Teachers Advisors LLC now owns 219,040 shares of the company’s stock valued at $595,000 after purchasing an additional 20,290 shares in the last quarter. Institutional investors and hedge funds own 84.53% of the company’s stock.

WARNING: “BioScrip (BIOS) Upgraded to “Buy” by BidaskClub” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://ledgergazette.com/2018/02/11/bioscrip-bios-upgraded-to-buy-by-bidaskclub.html.

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply